- 产品描述
- 产品组分
- 文件资源
- 营销中心
- 注意事项
- FAQ
- 文献追踪
-
胞嘧啶环中 5-碳上的甲基若具备共有原子价的条件,就能引发DNA 的甲基化,产生5-甲基胞嘧啶。现在有多种方法可用于DNA 甲基化状态的分析。但是,只有基因组DNA亚硫酸氢盐修饰,紧接着PCR 扩增,克隆,以及个体PCR 扩增引物排序,能对个体DNA分子上的个体胞嘧啶的甲基化状态提供可靠的信息。通过使用亚硫酸氢盐处理DNA,胞嘧啶残留物将被脱氨基成尿嘧啶,而5-甲基胞嘧啶则被完整的保留。
传统的亚硫酸氢盐转化方法需要12-16个小时进行亚硫 酸氢盐处理,DNA严重降解(>80%), 高不相称的甲基胞嘧 啶脱氨基(>3.5%),低胞嘧啶转化率<95%)。在2005年三 月份,我司成为第一个研发快速DNA亚硫酸氢盐修饰方法的公司,我司的方法客服了其他方法所存在的一系列问题—— 将亚硫酸氢盐过程从16小时缩短至只需要1.5小时,显著的提 高了胞嘧啶转化效率(>99.9%),并有效的防止了修饰后的 DNA降解。
一步法DNA甲基化修饰试剂盒的主要流程图为了有效的配备转化后的DNA用于各种下游分析,一种理想的亚硫酸氢盐修饰方法应该具备(1)高度精确允许胞嘧啶完全转化为尿嘧啶(正确的转化)而不会产生甲基胞嘧啶 脱氨基成为胸腺嘧啶(不正确的转化);(2)极速,使亚硫酸氢盐过程尽可能的缩短,因为对于基本研究,特别是临床应用,都要求要进行快速DNA甲基化分析。我司再接再厉创新研发一步法DNA甲基化修饰试剂盒,完美的演绎了DNA亚硫酸氢盐修饰方法,从而取得更好的DNA甲基化分析。一步法DNA甲基化修饰试剂盒是一套完整实验组件,它使用所特有的简化流线型亚硫酸氢盐法,来执行DNA甲基化分析。整个实验需要1小时45分钟,其结果远胜于其竞争对手。本试剂盒能适应于MS-PCR,实时定量MS-PCR,甲基化测序和焦磷酸测序等下游分析同于甲基化的微阵列。开发的一步法DNA甲基化修饰试剂盒。是专门针对提取好的DNA而设计的,具有如下的优势和特性: 目前市场快速的操作流程,一致的反应条件实验完成仅需要1小时45分钟。 彻底转换未甲基化的胞嘧啶为尿嘧啶,被修饰的DNA> 99·9%。 修饰过程中具备极低的DNA降解,能阻止超过90%的DNA损失。 DNA修饰最低要求:仅需要50pg或者20个细胞。 非常简单,可信赖的实验结果和稳定的修饰条件。 -
产品组分
组分内容
型号:A-P-1010-40(40次)
型号:A-P-1010-80(80次) 储存温度
G1
DNA Modification Powder 4 管 8 管 室温 G2 DNA Modification 5 ml 10 ml 室温 G3 Balance Solution 0.2 ml 0.4 ml 室温 G4 Modified DNA Capture 14 ml 28 ml 室温 G5 Modified DNA Cleaning 3 ml 6 ml 室温 G6 Modified DNA Elution 1 ml 2 ml 室温 F-spin Column 40个 80个 室温 F-Collection Tube
40个 80个 室温 操作手册
1
1 室温
*注意:在将离心柱放入微型离心机之前,始终将离心柱盖子旋紧盖严。配置好的G1/G2/G3溶液-20摄氏度放置最多一周。最好是即配即用。
-
文件资源
文件下载 文件内容 资源说明 
A-P-1010-一步法DNA甲基化修饰试剂盒 操作手册 
A-P-1028-快速MS-qPCR试剂盒相关产品 宣传单页 -
注意事项
保存建议 推荐蓝冰或冰袋运输。当您收到产品后,按照说明书建议保存各组分。 警告 本品仅供科研使用,请勿用于临床与诊断。 -
FAQ
-
Cao X et. al. (April 2020). The DNMT1/miR-34a/FOXM1 Axis Contributes to Stemness of Liver Cancer Cells. J Oncol. 2020:8978930.
Liang X et. al. et. al. (October 2019). The DNMT1/miR-34a Axis Is Involved in the Stemness of Human Osteosarcoma Cells and Derived Stem-Like Cells Hindawi Stem Cells International. 2019
Van Haute L et. al. (September 2019). NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs. Nucleic Acids Res. 47(16):8720-8733.
Van Haute L et. al. (May 2019). NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs bioRxiv.
Ntranos A et. al. (January 2019). Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis. Brain.
Gao XZ et. al. (December 2015). Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5‑aza‑2'‑deoxycytosine with potential therapeutic significance in Burkitt's lymphoma. Mol Med Rep.
Gabriel AS et. al. (August 2015). Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics. 10(8):717-26.
van Otterdijk SD et. al. (February 2015). Aberrations in DNA methylation are detectable during remission of acute lymphoblastic leukemia and predict patient outcome. Epigenomics. 7(1):35-45.
Gautrey HE et. al. (May 2014). DNA methylation abnormalities at gene promoters are extensive and variable in the elderly and phenocopy cancer cells. FASEB J.
Collerton J et. al. (April 2014). Acquisition of aberrant DNA methylation is associated with frailty in the very old: findings from the Newcastle 85+ Study. Biogerontology.
Wu X et. al. (April 2014). Epigenetic Signature of Chronic Cerebral Hypoperfusion and Beneficial Effects of S-adenosylmethionine in Rats. Mol Neurobiol.
Tang W et. al. (March 2014). RhoBTB2 gene in breast cancer is silenced by promoter methylation. Int J Mol Med. 33(3):722-8.
Wang CX et. al. (February 2014). Aberrant DNA methylation and epigenetic inactivation of hMSH2 decrease overall survival of acute lymphoblastic leukemia patients via modulating cell cycle and apoptosis. Asian Pac J Cancer Prev. 15(1):355-62.
Li KK et. al. (July 2013). MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 23(4):413-25.
Yuasa Y et. al. (December 2012). Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int J Cancer. 131(11):2596-603.
Calabuig-Fariñas S et. al. (October 2012). Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production. Pathol Oncol Res. 18(4):793-802.
Gallardo A et. al. (April 2012). Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 106(8):1367-73.
Thathia SH et. al. (March 2012). Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. 97(3):371-8.
Ferguson S et. al. (March 2011). The dual role of HLXB9 in leukemia. Pediatr Blood Cancer. 56(3):349-52.
Pang JC et. al. (November 2010). KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 20(6):1021-32.
Cheng ZD et. al. (February 2010). Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods. Chin J Cancer. 29(2):163-6.
Novara F et. al. (October 2009). Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 126(4):511-20.
Cheetham S et. al. (June 2008). SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer. 98(11):1810-9.
Otsubo T et. al. (February 2008). SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 98(4):824-31.
Treilleux I et. al. (July 2007). The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 51(1):63-9.
猜你喜欢
在线留言
如果您对我们的产品感兴趣,请留下您的信息,我们将尽快与您联系,谢谢!
艾维缔官网
艾德官网
B站IVDSHOW
抖音军哥聊表观
视频号艾维缔
小红书艾维缔
快手表观盒子
表观遗传学
联系我们
